M&A / Deals Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates Pharmaceutical TechnologyRegeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.Read full story pharminent May 19, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs. Read full story Post navigation Previous: SCOTUS won’t hear pharma’s IRA complaintsNext: VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026